Clinical trials: PD-L1
Non-Small Cell Lung Cancer
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the…
- Trial name
- NCT07096882
- Testing
- SDT-M001 injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Cytocraft Biopharmaceutical Co., Ltd.
Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate…
- Conditions
- Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
- Trial name
- NCT06504394
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 29 sites in United States, Australia and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This is a global, multi-center, Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs.
- Conditions
- Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE-003 (NCT06790966)
- Testing
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
- Where
- 28 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
Hepatocellular Cancer, Liver Cancer
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed…
- Conditions
- Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07911683
- Testing
- BGB-B2033
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Advanced Cancer
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1).
- Trial name
- NCT02805660
- Testing
- Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg
- Where
- 15 sites in United States
- Volunteers
- 83 people
- Sponsor
- Mirati Therapeutics Inc.
Non Small Cell Lung Cancer
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
To compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
- Trial name
- Cypress 1 (NCT03382899)
- Testing
- Pegilodecakin, Pembrolizumab
- Where
- 74 sites in United States
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
In the China extension study, Chinese participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or…
- Trial name
- NCT03850444
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 262 people
- Sponsor
- Merck Sharp & Dohme LLC
Merkel Cell Carcinoma
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with MCC who have progressed on or after anti-PD-L1 therapy.
- Trial name
- NCT03167164
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
Advanced or Metastatic Solid Tumors
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor. The dose escalation will follow the widely used 3+3 design.
- Trial name
- NCT03248843
- Testing
- KN035
- Where
- 2 sites in Japan
- Volunteers
- 35 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Cancer, Immunotherapy
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs)…
- Conditions
- Cancer, Immunotherapy, PD-1, PD-L1
- Trial name
- PROWES (NCT06635954)
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Oxford Biodynamics Inc.
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell…
- Trial name
- NCT02578680
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Volunteers
- 616 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Cancer
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel…
- Trial name
- NCT02256436
- Testing
- pembrolizumab, paclitaxel, vinflunine
- Volunteers
- 542 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Lymphoma
Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma
This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part…
- Trial name
- NCT04977167
- Testing
- HG146, PD-(L)1 antibody
- Where
- China
- Volunteers
- 24 people
- Sponsor
- HitGen Inc.
Diffuse Large B-Cell Lymphoma
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large…
- Trial name
- NCT02549651
- Testing
- MEDI4736, tremelimumab, AZD9150
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 32 people
- Sponsor
- MedImmune LLC
NSCLC
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC.
- Trial name
- NCT06361927
- Testing
- SSGJ-707
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Melanoma
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04303169
- Testing
- Pembrolizumab, Vibostolimab, Gebasaxturev
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable…
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Trial name
- GDFATHERHCC01 (NCT07219459)
- Testing
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 104 people
- Sponsor
- CatalYm GmbH
Advanced Melanoma
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of…
- Trial name
- NCT05549297
- Testing
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 540 people
- Sponsor
- Immunocore Ltd
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer